Meeting
2015 ASCO Annual Meeting
Is Next Generation Sequencing (NGS) Ready for Routine Clinical Practice in Gliomas? Results of a Prospective Study Utilizing the MSK-IMPACT Assay
Authors
Antonio Marcilio Padula Omuro
Memorial Sloan Kettering Cancer Center, New York, NY
Antonio Marcilio Padula Omuro , Ahmet Zehir , Donavan T. Cheng , Michael F. Berger , David Michael Hyman , David B. Solit , Jose Baselga , Marc Ladanyi , Maria E. Arcila , Meera Hameed , Paul Sabbatini , Lisa Marie DeAngelis , Philip H. Gutin , Marc Rosenblum , Ingo K. Mellinghoff , Viviane Tabar , Timothy An-thy Chan , Samuel Briggs , Jason T. Huse , Cameron W. Brennan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01775072
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2057)
DOI
10.1200/jco.2015.33.15_suppl.2057
Abstract #
2057
Poster Bd #
46
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
New ESMO scale for clinical actionability of molecular targets (ESCAT) for gliomas based on a multicentric real world data cohort using next-generation sequencing (NGS).
First Author: Oriol Mirallas
Poster
2018 ASCO Annual Meeting
Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq.
First Author: Razelle Kurzrock
Poster
2018 ASCO Annual Meeting
Comprehensive genomic profiling of brain tumors to provide targeted therapy options and diagnostic certainty for oligodendrogliomas.
First Author: Lee A. Albacker
Poster
2016 ASCO Annual Meeting
Next generation sequencing (NGS) of primary central nervous system tumors (CNST) as part of a personalized medicine cancer research program (PMRP) to identify alterations with sensitivity to targeted inhibitors.
First Author: Tara L. Benkers